Tagged with Europe

Spain ZeClinics is a Spanish CRO specialized in zebrafish research. Simone Calzolari, CEO, explains the technical and financial advantages of using zebrafish – not legally recognized as animals – in pharmaceutical development. The CEO explains that there are at least ten ongoing clinical studies with molecules that were screened with zebrafish,…

Spain With global ambitions, Atrys Health, a publicly traded Spanish health-tech company, is betting on telediagnosis and last-generation radiotherapy to lead the precision medicine race, not missing the Big Data opportunities along the way. Its executive president, Dr. Santiago de Torres, explains why nothing is “too fast” when aiming for a…

Italy Medac Pharma Italy’s Giovanni Sala describes the Italian affiliate’s unique portfolio of haematology, onco-urology, and neurosurgery products, as well as generics, and outlines the challenges of the Italian market.   … in Italy we have developed a dual strategy: on one side in-licence local generic products; while on the other…

Italy SIFI’s Fabrizio Chines outlines how the company is progressing in European ophthalmic markets, explains the added value it is bringing to the glaucoma field, and tells us about its orphan drug for acanthamoeba keratitisis.    … Germany and the UK are the next strategic targets, but in those markets we will…

Spain Jesús Aguirre, Minister of Health of Andalusia – Spain’s most populous region – explains in detail the COVID-19 protocols executed by his ministry and how they managed to keep ICU saturation levels low. In addition, Aguirre comments on the end of the region’s auction model in the procurement of medicines,…

Italy Massimo Scaccabarozzi, President of Farmindustria, discusses Italy’s response to the pandemic and the association’s key priorities, which include maintaining Italy’s position as a European leader in terms of production. Italy has a key role to play in the EU objective of guaranteeing continuity of supply during emergencies.   Italy became…

Europe When the COVID-19 pandemic struck in early 2020, Europe’s reliance on active pharmaceutical ingredient (API) and generic medicine suppliers outside of the continent was laid bare. In the face of crisis, countries like India and China understandably looked first to safeguard their own populations which, combined with supply chain strains…

Spain Accord’s Marc Comas highlights the company’s presence in Spain with leading oncology products, three biosimilars and investment in specialty pharma. He shares his views on the COVID pandemic, the future of the supply chain, the importance of Spain, Barcelona’s attractiveness for the pharma industry, and explains why Accord will be…

Europe Having moved early on a promising phase II monoclonal antibody, Almirall is inching closer to entering the Sanofi-dominated European market for eczema after posting, along with Eli Lilly, positive phase III results for Lebrikizumab. The Catalan company says it is on track for a 2023 launch on the continent; Lilly…

Europe In an extensive recent PharmaBoardroom conversation, EMA Head of Advanced Therapies Ana-Hidalgo-Simon highlighted some of the most important trends around advanced therapy regulation in Europe. Hidalgo-Simon touched on why moderate growth in regulatory applications is a positive development for the EMA, how patient insights are being better incorporated into the…

Europe Speaking exclusively to PharmaBoardroom, the EMA’s Head of Advanced Therapies Ana Hidalgo-Simon discusses steadily growing numbers of regulatory applications in the advanced therapy field, the vital importance of patient group insights, RWE collection and curation, hospital exemptions, manufacturing challenges, and more.   [Advanced] therapies are complex, difficult, and have a…

Spain AseBio is the association promoting the development of the Spanish biotechnology industry. Its general manager, Ion Arocena, lays out the main priorities for the country’s sector, including the need to reevaluate public funding mechanisms at a national and European level, and provides an explanation for Spain’s leadership in clinical trials…